BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial von Bockorny, Bruno, Semenisty, Valerya, Macarulla, Teresa, Borazanci, Erkut, Wolpin, Brian M., Stemmer, Salomon M., Golan, Talia, Geva, Ravit, Borad, Mitesh J., Pedersen, Katrina S., Park, Joon Oh, Ramirez, Robert A., Abad, David G., Feliu, Jaime, Muñoz, Andres, Ponz-Sarvise, Mariano, Peled, Amnon, Lustig, Tzipora M., Bohana-Kashtan, Osnat, Shaw, Stephen M., Sorani, Ella, Chaney, Marya, Kadosh, Shaul, Vainstein Haras, Abi, Von Hoff, Daniel D., Hidalgo, Manuel

Volltext

Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial von Bockorny, Bruno, Macarulla, Teresa, Semenisty, Valerya, Borazanci, Erkut, Feliu, Jaime, Ponz-Sarvise, Mariano, Abad, David Gutierrez, Oberstein, Paul, Alistar, Angela, Munoz, Andres, Geva, Ravit, Guillen-Ponce, Carmen, Fernandez, Mercedes Salgado, Peled, Amnon, Chaney, Marya, Gliko-Kabir, Irit, Shemesh-Darvish, Liron, Ickowicz, Debby, Sorani, Ella, Kadosh, Shaul, Vainstein-Haras, Abi, Hidalgo, Manuel

Volltext

Abstract CT177: A multi-center phase 2a trial of the CXCR4 inhibitor motixafortide (BL-8040) (M) in combination with pembrolizumab (P) and chemotherapy (C), in patients with metast... von Hidalgo, Manuel, Macarulla, Teresa, Semenisty, Valerya, Borazanci, Erkut, Feliu, Jaime, Ponz-Sarvise, Mariano, Abad, David Gutierrez, Oberstein, Paul, Alistar, Angela, Muñoz, Andres, Geva, Ravit, Guillén-Ponce, Carmen, Fernandez, Mercedes Salgado, Peled, Amnon, Chaney, Marya, Glicko-Kabir, Irit, Shemesh-Darvish, Liron, Ickowicz, Debby, Sorani, Ella, Kadosh, Shaul E., Vainstein-Haras, Abi, Bockorny, Bruno

Volltext